Insmed (INSM) Return on Capital Employed (2011 - 2026)
Insmed (INSM) posted quarterly Return on Capital Employed of 63.67% for Q1 2026, down 510.0% year-over-year from 15.53% in Q1 2025, and up 5.84% quarter-over-quarter from 67.62% in Q4 2025.
Insmed (INSM) Return on Capital Employed (2011 - 2026) Analysis & Trends
Insmed's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 63.67% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 510.0% year-over-year to 63.67%; the TTM figure through Mar 2026 stood at 63.67% (down 510.0% YoY), while the FY2025 annual figure was 74.39%, down 1075.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 63.67%, up from 67.62% in the prior quarter.
- The five-year high for Return on Capital Employed was 35.51% in Q1 2022, with the low at 85.84% in Q1 2024.
- The 5-year median for Return on Capital Employed is 54.92% (2025), against an average of 55.19%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed tumbled 4898 bps in 2024, then soared 2727 bps in 2025.
- Insmed's Return on Capital Employed stood at 40.28% in 2022, then sank by 60 bps to 64.41% in 2023, then increased by 22 bps to 50.43% in 2024, then slumped by 34 bps to 67.62% in 2025, then grew by 6 bps to 63.67% in 2026.
- Business Quant data shows INSM's Return on Capital Employed at 63.67% in Q1 2026, 67.62% in Q4 2025, and 57.78% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -36.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50.93% |
| Mar 31, 2026 | -63.67% |
| Dec 31, 2025 | -67.62% |
| Sep 30, 2025 | -57.78% |
| Jun 30, 2025 | -54.92% |
| Mar 31, 2025 | -58.57% |
| Dec 31, 2024 | -50.43% |
| Sep 30, 2024 | -49.40% |
| Jun 30, 2024 | -79.17% |
| Mar 31, 2024 | -85.84% |
| Dec 31, 2023 | -64.41% |
| Sep 30, 2023 | -57.61% |
| Jun 30, 2023 | -52.02% |
| Mar 31, 2023 | -36.86% |
| Dec 31, 2022 | -40.28% |
| Sep 30, 2022 | -45.68% |
| Jun 30, 2022 | -38.49% |
| Mar 31, 2022 | -35.51% |
| Dec 31, 2021 | -32.83% |
| Sep 30, 2021 | -31.99% |